Recall Urticaria: Aspirin Also Induces It

Cimbollek S, Ávila-Castellano MR, Labella M, Baynova K, Aramburu T, Quiralte J
Department of Allergy, Hospital Universitario Virgen del Rocío, Seville, Spain

doi: 10.18176/jiaci.0219

Key words: Recall urticaria. Aspirin.
Palabras clave: Urticaria de recuerdo. Aspirina.

Recall urticaria (RU) is a rare biological phenomenon characterized by hives only at the previously injected site when the patient is re-exposed from another source [1]. The most common example is that of patients who have previously received subcutaneous allergen immunotherapy (scAIT) and present focal skin reaction at the sites of previous allergen injections when a new allergen is administered or after marked environmental exposure to the allergen [1,2]. However, other stimuli such as foods [1] and drugs (eg, heparin [3,4] and levofloxacin [5]) have been involved.

We present a case of RU caused by nonsteroidal anti-inflammatory drugs (NSAIDs) in a patient who had previously received scAIT.

A 30-year-old woman with allergic rhinitis underwent scAIT to house dust mite (Depigoid *Dermatophagoides pteronyssinus* and *Glycyphagus domesticus*, Leti Lab) without incident. Complete tolerance to the maintenance dose was achieved without local reactions. Two years after discontinuation of scAIT, the patient experienced a local urticarial reaction with multiple hives at the previous injection sites 40 minutes after intake of 600 mg of ibuprofen. These symptoms recurred on at least 7 occasions when the patient was exposed to ibuprofen (5) and metamizole (2). The patient tolerated paracetamol without adverse effects.

A single-blind, placebo-controlled oral challenge with ibuprofen 600 mg was performed and elicited multiples hives

**Figure.** Clinical result of single-blind, placebo-controlled oral challenge with aspirin. A, Injection site before the challenge. B, Focal hives (white arrows) after challenge with a 300-mg dose.
over a well-defined area on both arms. A subsequent single-blind, placebo-controlled oral challenge with aspirin revealed the same reaction (Figure), although a controlled challenge with celecoxib was negative.

In the patient we report, the symptoms were elicited by various NSAIDs (ibuprofen, metamizole, and aspirin) and resembled the pattern of patients with a cross-reactive cutaneous phenotype of sensitivity to NSAIDs [6]. This observation suggests that the enzymatic inhibition of the cyclooxygenase type I isoform could play a role in the development of this specific reaction. The tolerance of highly selective cyclooxygenase type 2 inhibitors such as celecoxib in the present case reinforces this hypothesis. However, the nature of the relationship between COX-1 inhibition and the local immunological trace of mite remains largely unknown.

To our knowledge, this is the first report of recall urticaria after scAIT that was elicited with various NSAIDs. This phenomenon might be a new cutaneous subphenotype of cutaneous NSAID hypersensitivity in patients with respiratory allergy treated with scAIT.

**Funding**

The authors declare that no funding was received for the present study.

**Conflicts of Interest**

The authors declare that they have no conflicts of interest.

**References**